Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Cash & Equivalents (2020 - 2026)

Sight Sciences has reported Cash & Equivalents over the past 6 years, most recently at $92.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.59% year-over-year to $92.0 million; the TTM value through Dec 2025 reached $92.0 million, down 23.59%, while the annual FY2025 figure was $92.0 million, 23.59% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $92.0 million at Sight Sciences, roughly flat from $92.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $271.5 million in Q3 2021 and troughed at $35.6 million in Q2 2021.
  • A 5-year average of $152.4 million and a median of $138.1 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 518.74% in 2022 and later dropped 29.86% in 2023.
  • Year by year, Cash & Equivalents stood at $260.7 million in 2021, then decreased by 29.03% to $185.0 million in 2022, then decreased by 25.34% to $138.1 million in 2023, then decreased by 12.87% to $120.4 million in 2024, then decreased by 23.59% to $92.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for SGHT at $92.0 million in Q4 2025, $92.4 million in Q3 2025, and $101.5 million in Q2 2025.